9EH Stock Chart & Stats
€4.06
-€0.76(-15.77%)
At close: 4:00 PM EDT
€4.06
-€0.76(-15.77%)
Day’s Range― - ―
52-Week Range€1.89 - €8.45
Previous CloseN/A
Volume0.00
Average Volume (3M)120.00
Market Cap
€448.88M
Enterprise Value€1.44K
Total Cash (Recent Filing)€115.70M
Total Debt (Recent Filing)€970.43M
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Nov 04, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.49
Shares Outstanding113,059,330
10 Day Avg. Volume50
30 Day Avg. Volume120
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.10
Price to Sales (P/S)0.24
P/FCF Ratio96.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.01Price Target Upside23.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)0.15
Revenue Forecast (FY)€2.26B
Bulls Say, Bears Say
Bulls Say
Contracted Growth And Market ExpansionHigher guidance, major customer renewals and the oncology partnership expand covered lives and contracted revenue. These wins can improve multiyear visibility and support management’s target of over 25% revenue growth in 2027.
AI-Enabled Operating EfficiencyScaling automation can lower processing costs, accelerate clinical decisions and improve customer value without reducing reported clinical quality. Broader deployment provides a durable path to productivity gains and margin recovery.
Improved Cash Generation And DeleveragingPositive cash generation and sharply lower balance-sheet leverage improve financial flexibility compared with recent periods. This can support ongoing investment and reduce financing pressure, although profitability still needs to catch up.
Bears Say
Deep Losses And Margin PressurePersistent net losses and structurally lower gross margins constrain returns on capital and limit internally funded growth. The deterioration suggests cost, pricing or business-mix pressure that must reverse before earnings quality becomes durable.
High Net Debt And Limited Cash CoverageDespite improved debt-to-equity metrics, substantial net debt and modest projected operating cash flow leave limited coverage for interest, investment and maturities. Refinancing needs could constrain strategic flexibility over the next several quarters.
Membership And Medical-Cost HeadwindsExpected Medicaid, exchange and client-exit pressures can reduce covered lives and weaken revenue in affected services. Elevated medical expense ratios also increase reserving and underwriting uncertainty, making margin recovery less predictable.
9EH FAQ
What was Evolent Health’s price range in the past 12 months?
Evolent Health lowest stock price was €1.89 and its highest was €8.45 in the past 12 months.
What is Evolent Health’s market cap?
Evolent Health’s market cap is €448.88M.
When is Evolent Health’s upcoming earnings report date?
Evolent Health’s upcoming earnings report date is Nov 04, 2026 which is in 66 days.
How were Evolent Health’s earnings last quarter?
Evolent Health released its earnings results on Aug 06, 2026. The company reported €0.017 earnings per share for the quarter, beating the consensus estimate of -€0.009 by €0.026.
Is Evolent Health overvalued?
According to Wall Street analysts Evolent Health’s price is currently Undervalued.
Does Evolent Health pay dividends?
Evolent Health does not currently pay dividends.
What is Evolent Health’s EPS estimate?
Evolent Health’s EPS estimate is 0.05.
How many shares outstanding does Evolent Health have?
Evolent Health has 113,059,330 shares outstanding.
What happened to Evolent Health’s price movement after its last earnings report?
Evolent Health reported an EPS of €0.017 in its last earnings report, beating expectations of -€0.009. Following the earnings report the stock price went down -3.759%.
Which hedge fund is a major shareholder of Evolent Health?
Currently, no hedge funds are holding shares in DE:9EH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolent Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€5.01 (23.30% Upside)
€5.01 (23.30% Upside)
Blogger Sentiment
Bullish
DE:9EH Sentiment 100%
Sector Average 60%
Sector Average 60%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-54.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Evolent Health
Evolent Health, Inc., a prominent healthcare firm, operates through its subsidiary, Evolent Health LLC, to furnish clinical and administrative solutions to both healthcare payers and providers across the United States. Its operations are divided into two principal segments: Evolent Health Services and Clinical Solutions. The Evolent Health Services division delivers an integrated platform encompassing both administrative and clinical functions, specifically designed for health plan management and the oversight of population health. This includes essential financial and administrative support, such as managing health plan operations, risk assessment, robust analytics and reporting, and strategic leadership. A cornerstone of this segment is "Identifi," its proprietary technology, which intelligently aggregates and analyzes data, streamlines care workflows, and actively engages patients, all with the aim of achieving patient-centered and cost-effective population health outcomes. Conversely, the Clinical Solutions segment specializes in offering sophisticated care management services for various stakeholders involved in specialty care delivery. These services are crucial for organizations transitioning from traditional fee-for-service models to value-based care, accommodating their unique stage of development and prevailing market dynamics, particularly in the fields of oncology and cardiology. The overarching objective of this segment is a holistic improvement in the total cost of care. Founded in 2011, Evolent Health, Inc. maintains its corporate headquarters in Arlington, Virginia.
9EH Company Deck
9EH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a balanced mix of strong operational execution and growth momentum (notably 31% QoQ revenue growth, a 50% jump in Performance Suite revenue, raised 2026 revenue guidance, a large oncology deal, and meaningful AI progress) alongside notable near-term challenges (elevated MER, membership headwinds from Medicaid/exchange, timing variability in EBITDA recognition, and elevated net leverage). Management expressed confidence in 2027 growth (>25% revenue) and margin recovery driven by AI, Performance Suite maturation and cost actions, but acknowledged material macro- and client-specific risks that temper near-term financial clarity.View all DE:9EH earnings summaries9EH Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€5.01
▲(23.30% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month









